AZD-7268

Experimental drug

{{Drugbox | verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (2S)-2-[[4-[[2-(2,6-dichlorophenyl)acetyl]amino]phenyl]methyl]-1-ethylpyrrolidine-2-carboxylic acid | image = AZD-7268.svg | image2 = | width = 200 | alt = | caption = Chemical structure of AZD-7268 }}

AZD-7268 is an experimental drug that was developed as a potential treatment for inflammatory diseases. It is a selective antagonist of the bradykinin B1 receptor, which is involved in the inflammatory response.

Mechanism of Action

AZD-7268 functions by selectively inhibiting the bradykinin B1 receptor. The bradykinin receptors are part of the G protein-coupled receptor family and play a significant role in the inflammatory response and pain signaling. The B1 receptor is upregulated during inflammation, and its activation leads to the release of pro-inflammatory cytokines and other mediators. By blocking this receptor, AZD-7268 aims to reduce inflammation and alleviate pain associated with various inflammatory conditions.

Development and Research

AZD-7268 was developed by AstraZeneca, a global biopharmaceutical company. The drug was part of a research program aimed at finding new treatments for chronic inflammatory diseases. Preclinical studies showed that AZD-7268 could effectively block the bradykinin B1 receptor and reduce inflammation in animal models.

Clinical Trials

The development of AZD-7268 included several phases of clinical trials to assess its safety, efficacy, and pharmacokinetics in humans. However, the results of these trials have not been widely published, and the current status of the drug's development is not publicly available.

Potential Applications

The primary application of AZD-7268 was intended for the treatment of chronic inflammatory diseases such as rheumatoid arthritis, osteoarthritis, and other conditions characterized by excessive inflammation and pain. By targeting the bradykinin B1 receptor, AZD-7268 could potentially offer a novel therapeutic approach for patients who do not respond adequately to existing treatments.

Challenges and Considerations

Developing drugs that target the bradykinin B1 receptor presents several challenges. The receptor is not constitutively expressed in normal tissues but is induced during inflammation, making it a dynamic target. Additionally, the redundancy and complexity of the inflammatory pathways mean that blocking a single receptor may not be sufficient to achieve the desired therapeutic effect.

Related Pages

• Bradykinin
• Inflammation
• G protein-coupled receptor
• AstraZeneca